{
    "Trade/Device Name(s)": [
        "Simplexa COVID-19 & Flu A/B Direct",
        "Simplexa\u2122 COVID-19 & Flu A/B Direct"
    ],
    "Submitter Information": "DiaSorin Molecular LLC",
    "510(k) Number": "K220963",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN200031"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QOF",
        "OOI"
    ],
    "Summary Letter Date": "March 30, 2022",
    "Summary Letter Received Date": "April 1, 2022",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3981",
        "21 CFR 862.2570"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The SARS-CoV-2 Respiratory Infection And Other Microbial Agents When In A Multi-Target Test",
        "Real Time Nucleic Acid Amplification System"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "SARS-CoV-2 RNA",
        "Influenza A virus RNA",
        "Influenza B virus RNA"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab (NPS)"
    ],
    "Specimen Container(s)": [
        "Transport media"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON MDX"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time RT-PCR",
        "Direct amplification",
        "Fluorescent probe detection"
    ],
    "Methodologies": [
        "RT-PCR",
        "Molecular detection",
        "Multiplex nucleic acid amplification"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Software",
        "Accessory",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin Molecular Simplexa COVID-19 & Flu A/B Direct real-time RT-PCR assay for detection of SARS-CoV-2, influenza A, and influenza B RNA on the LIAISON MDX instrument",
    "Indications for Use Summary": "Qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B in nasopharyngeal swabs from individuals with respiratory infection symptoms, as an aid in differential diagnosis.",
    "fda_folder": "Microbiology"
}